NCT06528444 Clinical Trial Evaluating the Efficacy and Safety of Dexamethasone Compared to Placebo in Patients With Severe Influenza
| NCT ID | NCT06528444 |
| Status | Recruiting |
| Phase | Phase 3 |
| Sponsor | Instituto de Investigación Sanitaria y Biomédica de Alicante |
| Condition | Influenza |
| Study Type | INTERVENTIONAL |
| Enrollment | 42 participants |
| Start Date | 2024-10-01 |
| Primary Completion | 2028-10-31 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
Clinical trial with an active ingredient of a pharmaceutical specialty marketed in Spain vs. placebo. Randomized, double-blind, multicenter phase III clinical trial that evaluates the efficacy and safety of dexamethasone compared to placebo in patients with severe influenza.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥ 18 years. 2. Diagnosis of influenza A or B virus infection by antigen or RT-PCR (local laboratory) at the time of entry or at 48 hours prior to randomization in respiratory specimens (nasopharyngeal swab or bronchoalveolar lavage). 3. Hospitalized patients with an estimated hospital stay of more than 24 hours. 4. In previous treatment or concomitant start of treatment with oseltamivir. 5. For women of childbearing age, use of contraceptive methods until day 30 after completion of treatment. 6. Signed informed consent. Exclusion Criteria: * 1\. Patients with bronchial hyperresponsiveness that requires systemic corticosteroids for more than 24 hours. 2\. Pre-inclusion treatment with corticosteroids for more than 24 hours at a dose equal to or higher than 1 mg/kg methyl-prednisolone (0.2 mg/kg dexamethasone or 1.25 mg/kg prednisone). 3\. Inability to administer oral oseltamivir. 4. Patients on ECMO (extracorporeal membrane oxygenation). 5. Pre-existing condit